-+ 0.00%
-+ 0.00%
-+ 0.00%
Erasca Partners With Bristol Myers Squibb on Pancreatic Cancer Drug Trial
Share
Listen to the news
Erasca Partners With Bristol Myers Squibb on Pancreatic Cancer Drug Trial
  • Erasca entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate ERAS-0015 with navlimetostat.
  • The Phase 1/2 trial will test the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma.
  • Bristol Myers Squibb will sponsor the trial; its partner will supply ERAS-0015.
  • The agreement is nonexclusive, with each company retaining development and commercial rights to its respective compound.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611171840PRIMZONEFULLFEED9880026) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending